drugset / Trial / NCT04578847
A Study of REduction And DIscontinuation Treatment of TKI (Imatinib, Nilotinib, Dasatinib and Bosutinib)
NaSingle-groupOpen-labelTreatment
Summary
The main goal of this study is to evaluate the stability of molecular response (major and deep molecular response( MMR and DMR)) in patients with chronic myeloid leukemia (CML) with stable DMR after two-stage dose reduction phase and discontinuation treatment TKI: imatinib, nilotinib, dasatinib and bosutinib.
Timeline
- Start
- 2020-01-15
- Primary completion
- 2025-01-15
- Completion
- 2025-01-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bosutinib | Small molecule | 200 mg | — |
| Subject | Imatinib | Small molecule | 200 mg | — |
| Subject | Nilotinib | Small molecule | 200 mg | — |
| Subject | dasatinib anhydrous | Small molecule | 25 mg | — |